搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Complement Component 9, C9 ELISA Kit

Human Complement Component 9, C9 ELISA Kit

  • 中文名稱：
    人補(bǔ)體蛋白9(C9)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-E14011h
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人補(bǔ)體蛋白9(C9)酶聯(lián)免疫試劑盒（CSB-E14011h）為雙抗夾心法ELISA試劑盒，定量檢測(cè)血清、血漿、尿液樣本中的C9含量。人補(bǔ)體蛋白9(C9)是補(bǔ)體系統(tǒng)中的重要成分，參與膜攻擊復(fù)合物（MAC）的形成，對(duì)病原體和異常細(xì)胞具有溶解作用。其研究背景涉及衰老、神經(jīng)退行性疾病等，機(jī)制上與補(bǔ)體激活、炎癥反應(yīng)和細(xì)胞凋亡密切相關(guān)。試劑盒檢測(cè)范圍為10.97 pg/mL-8000 pg/mL，適用于科研領(lǐng)域中對(duì)補(bǔ)體系統(tǒng)功能的基礎(chǔ)研究，如炎癥反應(yīng)機(jī)制解析、自身免疫性疾病模型中的補(bǔ)體激活評(píng)估，或通過(guò)體液樣本探索C9在感染、腎臟疾病等病理?xiàng)l件下的生物標(biāo)志物價(jià)值本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說(shuō)明書。
  • 別名：
    C9; Complement component C9
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, urine
  • 檢測(cè)范圍：
    10.97 pg/mL-8000 pg/mL
  • 靈敏度：
    10.97 pg/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Immunology
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human C9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    SampleSerum(n=4)
    1:2000Average %96
    Range %90-104
    1:4000Average %91
    Range %87-98
    1:8000Average %95
    Range %90-110
    1:16000Average %96
    Range %89-100
  • 回收率：
    The recovery of human C9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9692-101
    EDTA plasma (n=4)9787-106
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    80002.577 2.514 2.546 2.455
    2666.71.845 1.864 1.855 1.764
    888.91.239 1.213 1.226 1.135
    296.30.851 0.844 0.848 0.757
    98.80.388 0.399 0.394 0.303
    32.90.214 0.207 0.211 0.120
    10.970.139 0.142 0.141 0.050
    00.089 0.093 0.091
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.
  • 基因功能參考文獻(xiàn)：
    1. The data supports the assumption that C9 gene expression may stimulate the expression of inflammatory (NLRP3) and angiogenic growth factors (VEGF) in retinal pigment epithelial cells. PMID: 30090015
    2. Serum-expressed apolipoprotein B-100 protein, C9 Complement, and gelsolin can be used for differential diagnosis of Barrertts esophagus and adenocarcinoma of esophagus. PMID: 26404905
    3. Data indicate that complement C9 binds to the ATPase domain of mortalin. PMID: 24719326
    4. Liver biopsy specimens from chronically hepatitis C virus-infected patients exhibited a lower level of C9 mRNA expression than liver biopsy specimens from unrelated disease or healthy control human liver RNA. PMID: 23487461
    5. the haploinsufficiency of C9, a terminal complement complex component, engenders reduced intraocular secretion of VEGF and decreased risk for CNV development. PMID: 22190594
    6. C9 and fucosylated form could serve as a useful marker for SQLC. PMID: 21840429
    7. It was concluded that variations in the complement component 9 gene are unlikely to influence clearance of chronic hepatitis B virus infection and hepatocellular carcinoma occurrence. PMID: 21380615
    8. Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. PMID: 21507937
    9. These results suggested that the lack of membrane attack complex because of an Arg95Stop mutation of the complement component 9 gene predisposed patients to pathognomonic glomerulonephritis. PMID: 21057849
    10. provided evidence for the recognition of membrane-bound C9 on complement-lysed ghosts by an antibody specific for the helix-turn-helix fold. PMID: 20153530
    11. Data show that mortalin supports cancer cell resistance to complement-dependent cytotoxicity and suggest consideration of mortalin as a novel target for cancer adjuvant immunotherapy. PMID: 19739077
    12. The human complement C9 gene: structural analysis of the 5' gene region and genetic polymorphism studies. PMID: 11881818
    13. C9 binding is dependent on the N-terminal modules (thrombospondin type 1 and low-density lipoprotein receptor class A) of C8 alpha together with the C8 alpha membrane attack complex/perforin domain. PMID: 12463754
    14. Founder effect was demonstrated for the R95X mutation of the C9 gene in Japanese PMID: 12596049
    15. results indicate that the principal binding site for C9 lies within the MACPF domain of C8alpha PMID: 16618117
    16. analysis of the CD59-C9 binding interaction PMID: 16844690

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Complement component 9 deficiency (C9D); Macular degeneration, age-related, 15 (ARMD15)
  • 亞細(xì)胞定位：
    Secreted. Target cell membrane; Multi-pass membrane protein.
  • 蛋白家族：
    Complement C6/C7/C8/C9 family
  • 組織特異性：
    Plasma (at protein level).
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 1358

    OMIM: 120940

    KEGG: hsa:735

    STRING: 9606.ENSP00000263408

    UniGene: Hs.654443